Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management

Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37^oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.